INTRODUCTION
The outer membrane of the Gram-negative bacteria is a lipid bilayer containing phospholipids in the internal layer and lipopolysaccharides (LPS) in the external leaflet. 1, 2 Embedded in this membrane, there are also several classes of porins, which control cell permeability by forming cross-membrane channels. 1, 2 LPS are complex toxic molecules composed of three distinct domains: the lipid A (possessing most of the biological properties of LPS); the R core oligosaccharide; and the highly variable O-antigenic polysaccharide. 1,2 LPS is not toxic unless it is released from the external layer of the outer membrane of lysed or growing bacteria. 1, 2 Responses to the blood invasion of Gram-negative bacteria in a host include fever, muscle proteolysis, weakness, hypotension, and, in some cases, uncontrolled disseminated intravascular coagulation (DIC), shock (septic shock), and/or serious multiple system organ failure (MSOF) that may lead ultimately to the death of the patient. [3] [4] [5] [6] [7] [8] [9] The lipid A portion of LPS has potent biological activities that are thought to cause many of the clinical features in this severe pathological condition. 2, 4 Although the pathogenesis of Gram-negative septic shock is not completely understood, the relevant symptoms appear to be mainly related to the production from monocytes/macrophages of IL-1β, TNF-α, and IL-6. [3] [4] [5] [7] [8] [9] [10] It has been suggested that microbial cell wall substances other than LPS released from lysed or growing Gram-negative bacteria may significantly contribute to the pathogenesis of the septic shock. 11 The occurrence of fever, leukopenia, and other systemic symptoms in individuals rendered tolerant to endotoxin also supports a role for factors other than LPS in the pathogenesis of this The effect of porins, major hydrophobic outer membrane proteins purified from Salmonella typhimurium, on human blood coagulation was investigated. It was found that micromolar concentrations of porins accelerated markedly human blood coagulation in vitro. Using appropriate experiments, data were obtained showing that the main target of the porin-induced procoagulant effect was thrombin. A possible binding of porins with thrombin has been suggested to be the basis of this effect. The implications of this finding in the pathogenesis of the disseminated intravascular coagulation syndrome (DIC) occurring during the Gram-negative septic shock is discussed. condition. 11, 12 This study investigated the role played by porins. These molecules are major hydrophobic outer membrane proteins (M r = ~35,000 in enteric bacteria) that are named porins for their ability to form trimeric transmembrane anion-selective channels for the passive diffusion of small hydrophilic compounds (cut-off ~600 Da) across the outer membrane. [13] [14] [15] [16] Purified porins possess immunomodulatory and pro-inflammatory [17] [18] [19] activities and are considered pathogenicity determinants. Depending on the dose, porins are either frankly toxic to a number of target cells or significantly alter normal cell functions. [20] [21] [22] Non-toxic concentrations of porins stimulate the synthesis and release of platelet activating factor (PAF) from different human cell types (PMNs, mesangial, endothelial cells, etc.) and other immunobiological activities. [23] [24] [25] [26] [27] Exposure of target cells to high or low concentrations of LPS or porins leads to their lysis or apoptotic death, respectively. 20, 21, [28] [29] [30] [31] [32] [33] [34] The ability of bacterial LPS and porins to damage or kill cells by necrosis and/or apoptosis has been suggested to play a key role in the pathogenesis of many consequences occurring in subjects infected by Gram-negative bacterial organisms.
On the basis of these data and considerations, we investigated the possible involvement of porins from Salmonella typhimurium in the pathogenesis of DIC, an acquired coagulation disorder that plays a pivotal role in the fatal outcome of many cases of endotoxic septic shock.
MATERIALS AND METHODS

Purification of porins
Porins were purified to homogeneity from S. typhimurium SH5014 (from the collection of the Istituto di Microbiologia, Facoltà di Medicina, Seconda Università di Napoli, Naples, Italy) according to the method of Nurminen 35 as described by Tufano et al. 24 In the sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) 36 profile of the purified preparation there were only two proteins: a major one with a MW of 34,000 Da and a minor one with a MW of 36,000 Da. The porin preparations (10 µg/ml) were LPSfree, as determined by the Limulus test, 37 SDS-PAGE, 36 and silver nitrate staining. 38 In all the experiments, endotoxin-free water was used. The porin concentrations used in the experiments reported in this paper were those found at the plateau level after the linear part of preliminary dose-effect curves (data not shown).
Preparation of platelet-free plasma (PFP)
PFP was prepared from the venous blood of young, healthy, non-smoking individuals. Following addition of 0.11 M sodium citrate (9:1, v/v), 39 the blood samples were centrifuged at 15,000 g for 10 min at 4°C. The platelet-free supernatant was carefully separated from the pellet and immediately used as PFP in the experiments.
Preparation of normal blood serum
Blood serum was prepared aiming to evaluate the antithrombin (AT) and thrombin-antithrombin (TAT) complexes at different times after clot formation. Blood samples from normal individuals were allowed to coagulate in glass tubes for 30 and 50 min at 37°C. After centrifugation at room temperature for 10 min at 3000 g, sera were taken and assayed at once for their content in AT or TAT complexes, following addition of 0.2 M sodium citrate (9:1, v/v) to stop the Ca 2+ ion-dependent coagulation reactions.
Coagulation time of recalcified plasma (RT)
The evaluation of the RT was carried out with a technique similar to Howell's original method, 40 using PFP instead of platelet-rich plasma (PRP). The assay was performed at 37°C by mixing 100 µl of 25 mM CaCl 2 with 100 µl of PFP and 100 µl of either 1.5 µM porins or 1.5 µM LPS (Difco Laboratories, Detroit, MI, USA; MW ~100 kDa) solution and recording the coagulation time. The final concentration of both porins and LPS in the reaction mixtures was 0.5 µM. A control was obtained by using 100 µl of 154 mM NaCl instead of porin or LPS solution.
Prothrombin time (PT)
This test was performed with a PT kit (Boehringer, Milano, Italy). Thromboplastin (T, 100 µl) in the form of rabbit brain acetone extract was added to a 300 µl reaction mixture prepared by mixing 100 µl of 25 mM CaCl 2 with 100 µl of PFP and 100 µl of either 2 µM porins or 2 µM LPS. The final concentration of both porins and LPS in the reaction mixtures was 0.5 µM. The clotting time was recorded upon incubation at 37°C. A control was obtained by using 100 µl of 154 mM NaCl instead of the porin solution.
Activated partial thromboplastin time (APTT)
The assay was carried out by mixing 100 µl of PFP with 100 µl of celite-containing PTT reagent (Boehringer) and 100 µl of either 2 µM porins or 2 µM LPS or 154 mM NaCl (control). After incubation at 37°C for 3 min, 100 µl of 25 mM CaCl 2 was added to this mixture and the coagulation time was recorded. The final concentration of both porins and LPS in the reaction mixtures was 0.5 µM.
Serum residual prothrombin test (SRPT)
A PT kit from Boehringer was used to perform this test. The assay mixture was prepared by mixing 100 µl of PFP, 100 µl of 25 mM CaCl 2 , and 100 µl of either 1.5 µM porins or 1.5 µM LPS or 154 mM NaCl (control). The final concentration of both porins and LPS in this reaction mixture was 0.5 µM.
After allowing the assay mixture to stand at 37°C for 50 min for clot formation, 100 µl of serum produced from each plasma clot was added to another reaction mixture containing 100 µl of prothrombin-deficient plasma, 100 µl of rabbit brain acetone extract, and 100 µl of 25 mM CaCl 2 . The clotting time was recorded and expressed as a percentage of SRPT, its value being inversely proportional to the amount of residual prothrombin present in the serum analyzed. The micromolar concentration of prothrombin in these sera was calculated from a calibration curve obtained with sera having a known titer of prothrombin.
In vitro effect of porins and/or antithrombin (AT) on a simplified coagulation system
These experiments were carried out with a simplified coagulation system made of pure human fibrinogen (Sigma-Aldrich, Milan, Italy), human thrombin (Sigma-Aldrich), and bovine lung heparin (Calbiochem, Milan, Italy). Different incubation mixtures were prepared by mixing 200 µl of a solution of thrombin and heparin (7.34 µM and 0.1 U/ml, respectively) in 154 mM NaCl with 200 µl of 154 mM NaCl containing or not (control) either 0.75-7.5 µM human antithrombin (AT; Sigma-Aldrich) alone, or 0.9 µM of either porins or LPS alone, or 0.9 µM porins plus 0.75 or 7.5 µM AT. After incubation at 37°C for 4 min, 150 µl of 1.32 µM fibrinogen, also pre-heated at 37°C for 4 min, was added to 100 µl aliquots of the various reaction mixtures and the coagulation time was recorded. The blanks used were incubation mixtures without thrombin and heparin.
Thrombin esterase activity
The assay was performed at room temperature by using tosyl-gly-pro-arg-5-amino-2-nitrobenzoic acid isopropylamide (Behring, Milano, Italy) as the chromogenic substrate of the thrombin esterase activity. The reaction mixture (Tris-HCl buffer, pH 8.2, 0.6 ml) contained 340 µM substrate, 1.5 µM thrombin/0.02 U/ml heparin, 154 mM NaCl, and different concentrations of porins, LPS or AT, where required. The absorbance (A) at 405 nm was measured at room temperature every minute for a total time of 10 min. The ∆A 405 /min was calculated as follows:
Eq. 1
where Σ∆A 405 /min = sum of the different absorbance values, taken every minute at 405 nm for a total time of 10 min, minus the absorbance at 405 nm taken immediately after the chromogenic substrate addition to the reaction mixture (control value); 10 = total duration, in minutes, of the thrombin esterase reaction.
Quantitation of AT in plasma and serum
The AT concentration was immunologically measured by the NOR-Partigen-Antithrombin III Kit (Behring, Marburg, Germany) according to the manufacturer's instructions. 39 The determination was based on an immunodiffusion technique using either rabbit or sheep polyclonal antibodies (components of the Behring kit) as immunological reagents.
The AT levels were also evaluated by a spectrophotometric technique described in detail elsewhere. 41 In this technique, the assay was kinetic, the absorbance measurements were performed at 405 nm, and the chromogenic substrate used was the tosyl-gly-pro-arg-5-amino-2-nitrobenzoic acid isopropylamide (Behring).
Evaluation of serum thrombin-antithrombin (TAT) complexes
The TAT concentration was determined by immuno-enzymatic analysis in sera obtained from blood coagulated in the absence or in the presence of porins or LPS. The sera used were separated from coagulated blood at different times (30 and 50 min) after clot formation. The TAT complexes were evaluated by using the Enzygnost TAT assay kit (Enzyme Immunoassay for the determination of human thrombin/antithrombin III complex, Behring) according to the manufacturer's instructions. 39, 42 
Statistical analysis
Data are reported as means ± SEM of determinations performed in triplicate on a suitable number (see notes to tables) of different experiments. The means were compared using analysis of variance (ANOVA) plus Bonferroni's t-test, and a P value of less than 0.05 was considered significant.
RESULTS
The blood RT, but not PT, APTT, and SRP, is markedly reduced by porins
Different parameters of the blood clotting cascade were measured in vitro in the presence or in the absence of porins or LPS. Micromolar concentrations of both porins and LPS did not alter the normal PT, APTT, and SRP values. In contrast, porins, but not LPS, reduced by about 40% the RT value (data not shown). Similar results were obtained with higher concentrations (1 and 2 µM) of porins, whereas equimolar or higher (2 and 5 µM) concentrations of LPS, did not produce any procoagulant effect.
The presence of porins during the blood clotting process does not modify the serum concentration of both AT and TAT
The marked decrease of RT induced by porins suggested the possibility that these proteins could interfere with the thrombin enzymatic activity either directly or indirectly via AT. Using appropriate experiments, we demonstrated that both serum AT and TAT concentrations were not significantly modified by the presence of either porins or LPS during the blood coagulation process (data not shown). This finding strongly suggested that the porins did not interact with thrombin via AT.
The CT and the thrombin esterase activity of a purified clotting system are markedly modified by porins: the changes are modulated by AT
We have suggested the possibility that the porins accelerate blood coagulation by acting directly on thrombin activity. On the other hand, it is well known that thrombin esterase activity is proportional to the thrombindependent proteolytic attack of fibrinogen, a critical step in the process of blood coagulation. Consequently, we measured both the esterase and the clotting activity of a defined amount of thrombin in a purified in vitro system with or without porins or LPS. The upper curve in Figure  1 , which has a hyperbolic trend, shows that thrombin esterase activity, as measured with a synthetic substrate (see Materials and Methods), depends on porin concentration (solid line with solid circles). It can be hypothesized that these experimental data most probably reflect binding between porins and thrombin. A double reciprocal plot (1/∆A 405 versus 1/[porin]) of the experimental data has been found to have a linear biphasic trend (data not shown) that suggests a possible interaction of porins with two non-equivalent independent thrombin sites (sites 1 and 2), each characterized by its own maximum velocity. This conclusion can be mathematically expressed by the following equation: (Fig. 2) .
The data in Table 1 confirm the stimulating effect of porins on the thrombin esterase activity and demonstrate that porins are able to reduce markedly the inhibitory effect of AT on the thrombin esterase activity when porins and AT were used in combination. It is also worth noting that in 
The experimental values used to prepare the graph are the means of 8 different determinations performed in triplicate. The SEM of the different means obtained varied in the range of ± 5-10%. Experimental details are described in Materials and Methods. our experimental conditions, all of the observed effects were always attributable to porins and never to LPS, even when the latter was used at concentrations higher than 0.5 µM (the use of 2 or 5 µM LPS in the reaction mixtures did not change the thrombin esterase activity or the CT of the purified clotting system; see notes to Tables 1 and 2 ).
Another important piece of evidence comes from the experiments summarized in Table 2 . These data show that micromolar concentrations of porins produce a marked decrease (76%; C/T ratio = 0.24) of the fibrinogen CT and reduce to about half the ability of AT to inhibit the fibrinogen coagulating activity of thrombin (change of the C/T ratio from 4.92 or 22.63 to 2.1 or 11). Also in this case, the addition of LPS in the 0.5-5 µM range to the system was ineffective.
DISCUSSION
The data reported in this paper point to thrombin as the specific molecular target of the porin-dependent procoagulant effect in vitro. The absence of porin effects on some important parameters of the blood clotting cascade, such as PT, APTT, and the SRP concentration strongly suggests that porins do not influence the prothrombinase-catalyzed Porin-induced activation of thrombin 215 production of thrombin from prothrombin, thus ruling out all the factors of the coagulation cascade upstream from the prothrombinase as molecular targets for the porin-induced procoagulant effect. The porin-induced RT decrease is probably related to the fact that under the experimental conditions of the RT assay, the rate of thrombin formation was sufficiently slow to allow porins to amplify the thrombinfibrinogen interaction. From these data, it can be inferred that only two molecules are the possible targets of the procoagulant effect of porins, namely thrombin, fibrinogen, or both. If thrombin was the main target of the porin effect, then this effect could be either direct or indirect via AT. The latter assumption can be ruled out because neither serum AT nor TAT concentration was modified by the presence of porins during the coagulation process. The data supporting the first hypothesis derive from the experiments performed with purified in vitro systems. These assays demonstrate that porins: (i) have a stimulatory effect on the fibrinogen CT; and (ii) stimulate the thrombin esterase activity, which in turn is AT-modulated, thus suggesting that thrombin is the best target for the porin-dependent procoagulant activity (see Tables 1 and 2 , and Fig. 1 ). Although the lack of porin action on PT and APTT excludes fibrinogen as the main culprit of the porin-induced effect, no direct data are presently available to support this contention. At the molecular level, excluding the possibility that two thrombin isoforms can occur in our assays, it is likely that porins bind two non-equivalent independent thrombin sites, as suggested by the data reported in Figure 1 . The specific equation used allowed us to obtain thrombin esterase velocity data at any porin concentration and suggested that the stimulating effect of this protein on the thrombin esterase reaction could be mediated by an increase of the catalytic constant. Although a porin-substrate interaction cannot be ruled out, structural modifications could be produced at the level of the thrombin active site during interaction of porins with the two exosites flanking the catalytic groove, allowing a better action of the enzyme on its synthetic or physiological substrates. 43, 44 This possibility is also supported by the fact that the inhibitory action of the heparin-activated AT is significantly modified when this regulatory serpin is added to the reaction mixture in combination with micromolar porin concentrations (see Tables 1 and 2 ). Finally, preliminary experiments performed with various techniques (acrylamide gel retardation electrophoresis, binding of radioactive porin to thrombin adsorbed on plates, etc.) have indicated that the porin possesses the ability to form in vitro sufficiently stable non-covalent complexes with thrombin (data not shown). In conclusion, these data strongly support the hypothesis that thrombin is a direct molecular target of the porins procoagulant effect.
The data reported in this paper clearly show that the S. typhimurium porins are capable of accelerating human blood coagulation in vitro via a direct selective stimulation of thrombin activity. To our knowledge, this is the first example reported in the literature of a protein with a direct positive regulatory effect on thrombin. LPS does not share this property, even though it has a powerful capacity to stimulate the extrinsic and intrinsic pathways of blood clotting by inducing the expression of Factor III (tissue factor) on the plasma membrane of a number of cells (monocytes/macrophages, endothelial cells, etc.). [3] [4] [5] [6] [7] [8] [9] [10] On these grounds, we hypothesize that the condition of hypercoagulability occurring in individuals affected by Gram-negative sepsis might result from a strong porin-dependent amplification of thrombin activity produced by the LPS-induced activation of the intrinsic and extrinsic pathways of the blood clotting cascade. 6, 7 We presume that the effects induced by LPS in vivo could be amplified by LPS-associated porins. This, perhaps, might explain the poor results obtained in the therapy of the septic shock syndrome with anti-LPS antibodies. 45 Neutralization of porins by anti-porin antibodies might be useful to ameliorate significantly the outcome of the current therapeutic intervention in this severe pathological condition. 1, 5, 7, 8, 10, 45, 46 To verify this hypothesis, however, further in vivo experiments are required.
